Babud Takardu na CD19
Muhimman bugagun binciken asibiti daga abokan haɗinmu da ke tallafawa ci gaban maganin CAR-T.
Anti-CD19 CAR-T tare da IL-6 Knockdown don CNS B-ALL
Binciken asibiti na mataki na 1 (NCT03064269) na ssCART-19s da ke nufin CD19 tare da shirye-shiryen shRNA-6 don cutar B-cell ALL ta CNS. Ɗalibai uku sun sami warware alamu kusa da cikakkiyar, rage yawaitar shigarwa a cikin kwakwalwa a kan MRI, kuma ƙwayoyin CSF sun zama marasa kyau. An kawai lura da CRS na darajar 1. PubMed: 32745961
68Ga-labeled Ƙwayoyin CAR-T don PET Tracking a cikin Jiki
Binciken yuwuwar amfani da 68Ga gajarta rayuwa maimakon 89Zr don hoton PET na ƙwayoyin CAR-T ba tare da tiyata ba. Rage adadin radiation da aka sha da sau 24 yayin da aka kiyaye haɗin tare da rarraba ƙwayoyin dogon lokaci. Lafiya don fassarar asibiti. PMC: 8115074
CD19 CAR-T daga Masu Ba da don MPAL Bayan AlloHSCT
Rahoton lamari na CD19 CAR-T na biyu daga masu ba da ɗan adam wanda ya haifar da warwarewa a cikin cutar binta mai haɗakar halitta da ta sake dawowa/ba a iya magance ta bayan watsa tantinin jini daga wani. PubMed: 32874588
CAR-T a matsayin Hanya zuwa AlloHSCT don Ph+ MPAL
Maganin CAR-T a matsayin hanya zuwa watsa tantinin jini daga wani yana ba da warwarewa mai dorewa na cutar binta mai haɗakar halitta tare da chromosome na Philadelphia tare da ƙarancin ƙwayoyin cuta. PubMed: 32700338
AlloHSCT Bayan CD19 CAR-T don Ph+ ALL (n=56)
Nazarin manya 56 da ke da r/r Ph+ ALL: 91.1% CR/CRi tare da humanized CD19 CAR-T. AlloHSCT na haɗawa ya inganta shekaru 2 OS (58.9% vs 22.7%) da LFS (53.2% vs 18.8%). MRD-ba tare da bayan CAR-T ya kasance abin da ya dogara da hasashen. PMC: 13063648
Rage IL-6 yana rage sakin IL-6 na Monocyte
Binciken rage IL-6 a cikin tantanin halitta na CART-19 wanda ke nuna raguwar fitar da IL-6 daga monocytes, wanda zai iya rage haɗarin CRS da CRES. PMC: 8973323
CAR-T CD19/BCMA Biyu a Tsari Guda don Myeloma da yawa
Bayyana sabon bispecific CAR (tan-CAR) tare da scFv-BCMA da scFv-CD19 a tsari guda don nufin antigens biyu akan tantanin halitta na MM da kuma magance gudu na antigen. Nature: s41467-024-47801-8
CAR-T Anti-CD19 don Sake dawowa na B-ALL a fata da kuma ƙwayar mahaifa
Rahoton yanayin nasarar maganin sake dawowar B-ALL na waje a fata da kuma ƙwayar mahaifa ta amfani da CAR-T anti-CD19 tare da rage IL-6 — wuraren waje da ba a saba gani ba. PMC: 7204010
CAR-T CD22/CD19 a tsari don Ph-Like B-ALL na yara
Rahoton yanayin shan magani na biyu na CAR-T anti-CD22 da anti-CD19 daga mai ba da haihuwa wanda ya kai cikakken jin daɗi na huɗu a cikin yaro mai Ph-like B-ALL wanda ya sake dawowa bayan CAR-T na kai da haplo-HSCT. PMC: 6438143
CAR-T CD19 don Ph+ ALL tare da T315I Mutation
Marasa lafiya bakwai masu Ph+ ALL da T315I mutation da aka bi da su ta amfani da CAR-T CD19 kafin ko bayan alloHSCT. 6/7 sun kai CR cikin wata 1. An tabbatar da inganci da kuma iya aiki tare da ponatinib. PMC: 10656679
Hana ACAT-1 yana ƙara ƙarfin CAR-T don Ciwon Pancreas
Sabuwar dabarar hana enzyme esterification na cholesterol ACAT-1 a cikin tantanin halitta na CAR-T mai nufin mesothelin, wanda ke nuna ƙarfin kashe ƙwayoyin cuta mafi girma, ƙara fitar da IL-2/IFN-γ, da kuma raguwar ciwon daji a cikin xenografts na ciwon pancreas. PMC: 7063140
Ƙarfafa Radiation kafin CAR-T don DLBCL mai yawan abubuwan da ke ciki
Gwajin mataki na II (NCT03196830): Radiotherapy kafin CAR-T a cikin R/R DLBCL tare da yawan ciwon daji ya kai 100% ORR idan aka kwatanta da 25% tare da chemotherapy, tare da raguwar CRS (0% vs 100%) da neurotoxicity (0% vs 75%). PubMed: 31219975
CAR-T daga wani mutum don Myeloma da yawa mai dawowa/Rashin amsawa
Marasa lafiya huɗu masu RRMM da aka bi da su ta amfani da CART-19 da CART-BCMA daga masu ba da kaya marasa daidaitawa na HLA. Shan magani a sashi na tantanin halitta na CAR-T na bishiyoyi biyu tare da lura da bunƙasa a cikin jiki ta PCR. PMC: 9986336
CART19 vs ASCT don B-NHL mai dawowa/Rashin amsawa
Nazarin kwatanta na tsakiya guda na maganin CAR-T CD19 da kuma shuka tantanin halitta na kai a matsayin magani na yau da kullum don lymphoma na B-cell marasa Hodgkin mai dawowa/rashin amsawa. PMC: 6777912
CAR-T CD19/CD22 da aka yi da mutane a tsari bayan gazawar CAR-T na beri
An samu jin daɗi bayan wani lokaci ta hanyar shan magani a tsari na tantanin halitta na CAR-T CD19 da CD22 da aka yi da mutane a cikin marar lafiya mai r/r ALL wanda ya sake dawowa bayan CAR-T CD19 na beri. PubMed: 30988623
Hana Esterification na Cholesterol yana ƙara ƙarfin CAR-T
Hana ACAT-1 ta hanyar Avasimibe a cikin tantanin halitta na CAR-T CD19 na mutane ya ƙara ƙarfin kashe ƙwayoyin cuta bisa ga sashi, ya ƙara fitar da IFN-γ, kuma ya inganta rabon CD8/CD4 — sabuwar dabarar haɗin magani ta hanyar daidaita metabolism na T-cell. PubMed: CJI.0000000000000207
Maganin CAR-T don Leukemia na Myeloid Acute — Bita
Cikakken bita na ci gaban maganin tantanin halitta na CAR-T don AML gami da nazarin asibiti, gwaje-gwaje na asibiti, alamun saman da zasu iya zama, da dabarun magance ƙalubalen da ke cikin maganin AML a yau. PubMed: 41537901
Bayanan Dogon Lokaci na U16 (CAR-T CD20) — ASH 2024
Bin diddigin dogon lokaci na allurar U16 a cikin marasa lafiya 16 masu R/R B-NHL wadanda ba sa amsa rituximab: 100% ORR, 68.75% CR, matsakaicin PFS watanni 14.5, matsakaicin OS ba a kai ba. Aminci mai kyau ba tare da CRS na mataki na 4 ba.
Tantanan Halitta Masu Bayyana Antigen (TAET) don Share MRD — ASH 2024
Sabuwar dabarar da ke nuna cewa kunna CAR-T ya dogara da iyakar antigen. Tantanan halitta na CD19+ TAET suna sake dawo da ikon CAR-T na kashe ciwon daji a cikin yanayin ƙarancin ciwon daji, suna ba da damar share MRD sosai.